Bionomics Limited Files Amendment to Annual Report

AI Summary

BIONOMICS LIMITED/FI (NEUP) filed a Amended Foreign Annual Report (20-F/A) with the SEC on January 17, 2024. Bionomics Limited filed an amendment (20-F/A) to its annual report for the fiscal year ended June 30, 2023. The filing was made with the SEC on January 17, 2024. The company's principal executive offices are located at 200 Greenhill Road, Eastwood SA 5063, Australia. Spyridon "Spyros" Papapetropoulos, M.D. is the President and Chief Executive Officer. 1,486,735,424 ordinary shares were outstanding as of June 30, 2023.

Why It Matters

For investors and stakeholders tracking BIONOMICS LIMITED/FI, this filing contains several important signals. This amendment provides updated information for the fiscal year ending June 30, 2023, which is crucial for investors to understand the company's current status and reporting compliance. The filing confirms the company's legal structure, executive leadership, and the number of outstanding ordinary shares, offering transparency to stakeholders.

Risk Assessment

Risk Level: low — BIONOMICS LIMITED/FI shows low risk based on this filing. The filing is an amendment to a routine annual report, indicating no new material events or significant changes that would elevate risk.

Analyst Insight

Review the full amendment for any specific disclosures or changes that may impact investment decisions.

Key Numbers

• 1,486,735,424 — Ordinary Shares Outstanding (As of June 30, 2023)
• 2023-06-30 — Fiscal Year End (Report period)
• 2024-01-17 — Filing Date (Amendment filing date)

Key Players & Entities

• BIONOMICS LIMITED (company) — Registrant name
• Ernst & Young (company) — Auditor
• Spyridon "Spyros" Papapetropoulos, M.D. (person) — President and Chief Executive Officer
• BNOX (company) — Trading Symbol
• The Nasdaq Global Market (company) — Exchange
• Australia (company) — Jurisdiction of incorporation

FAQ

Industry Context

Bionomics Limited operates in the pharmaceutical preparations industry, focusing on the development of therapeutic agents.

Regulatory Implications

The company is subject to SEC regulations for its filings, including annual reports (Form 20-F) and amendments, ensuring transparency for investors.

What Investors Should Do

1. Review the full 20-F/A filing for detailed disclosures.
2. Monitor future SEC filings for ongoing company updates.
3. Verify share structure and executive information against company announcements.

Key Dates

• 2023-06-30: Fiscal Year End — End of reporting period for the annual report.
• 2024-01-17: Filing Date — Date the amendment to the 20-F was filed with the SEC.

Year-Over-Year Comparison

This filing is an amendment (20-F/A) to the previous annual report, indicating updates or corrections rather than a new initial filing.

Filing Documents

• bnox-20230630.htm (20-F/A) — 91KB
• bnox-ex12_1.htm (EX-12.1) — 16KB
• bnox-ex12_2.htm (EX-12.2) — 16KB
• 0000950170-24-004818.txt ( ) — 356KB
• bnox-20230630.xsd (EX-101.SCH) — 72KB
• bnox-20230630_htm.xml (XML) — 11KB

Controls and Procedures

Controls and Procedures Evaluation of Disclosure Controls and Procedures We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)) that are designed to ensure that information required to be disclosed in ours reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer, Non-Executive Chairman, and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Our management, with the participation of our Chief Executive Officer, Non-Executive Chairman and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2023. Based upon that evaluation, our Chief Executive Officer, Non-Executive Chairman and Chief Financial Officer concluded that, as of June 30, 2023, our disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level. Management’s Annual Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer, Non-Executive Chairman and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of June 30, 2023, based on the criteria set forth in Internal Control—Integra

SIGNATURES

SIGNATURES The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this annual report on its behalf. BIONOMICS LIMITED Date: January 16, 2024 By: /s/ Spyridon Papapetropoulos, M.D. Name: Spyridon Papapetropoulos. Title: Chief Executive Officer and Director By: /s/ Timothy Cunningham Name: Timothy Cunningham Title: Chief Financial Officer

View Full Filing

View this 20-F/A filing on SEC EDGAR